Float Short %

2.64

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.1

EPS Last/This Y

0.67

EPS This/Next Y

0.45

Price

0.45

Target Price

5.5

Analyst Recom

Performance Q

-36.06

Relative Volume

0.64

Beta

2.83

Ticker: ITRM

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	ITRM	0.5985	N/A	N/A	0
2025-11-11	ITRM	0.6098	N/A	N/A	0
2025-11-12	ITRM	0.5928	N/A	N/A	0
2025-11-13	ITRM	0.5793	N/A	N/A	0
2025-11-14	ITRM	0.4801	N/A	N/A	0
2025-11-17	ITRM	0.3675	N/A	N/A	0
2025-11-18	ITRM	0.3941	N/A	N/A	0
2025-11-19	ITRM	0.3916	N/A	N/A	0
2025-11-20	ITRM	0.3651	N/A	N/A	0
2025-11-21	ITRM	0.3898	N/A	N/A	0
2025-11-24	ITRM	0.4346	N/A	N/A	0
2025-11-25	ITRM	0.438	N/A	N/A	0
2025-11-26	ITRM	0.4718	N/A	N/A	0
2025-12-01	ITRM	0.4541	N/A	N/A	0
2025-12-02	ITRM	0.419	N/A	N/A	0
2025-12-03	ITRM	0.4214	N/A	N/A	0
2025-12-04	ITRM	0.4474	N/A	N/A	0
2025-12-05	ITRM	0.4675	N/A	N/A	0
2025-12-08	ITRM	0.4482	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	ITRM	0.60	-	-	-0.33
2025-11-11	ITRM	0.61	-	-	-0.33
2025-11-12	ITRM	0.59	-	-	-0.33
2025-11-13	ITRM	0.58	-	-	-0.33
2025-11-14	ITRM	0.48	-	-	-0.33
2025-11-17	ITRM	0.37	-	-	-0.33
2025-11-18	ITRM	0.40	-	-	-0.33
2025-11-19	ITRM	0.38	-	-	-0.33
2025-11-20	ITRM	0.37	-	-	-0.33
2025-11-21	ITRM	0.39	-	-	-0.33
2025-11-24	ITRM	0.43	-	-	-0.59
2025-11-25	ITRM	0.44	-	-	-0.59
2025-11-26	ITRM	0.47	-	-	-0.59
2025-12-01	ITRM	0.45	-	-	-0.59
2025-12-02	ITRM	0.41	-	-	-0.59
2025-12-03	ITRM	0.42	-	-	-0.59
2025-12-04	ITRM	0.45	-	-	-0.59
2025-12-05	ITRM	0.47	-	-	-0.59
2025-12-08	ITRM	0.45	-	-	-0.59
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	ITRM	1.45	3.05	2.43
2025-11-11	ITRM	1.88	3.05	2.43
2025-11-12	ITRM	1.88	3.05	2.86
2025-11-13	ITRM	1.88	3.05	2.86
2025-11-14	ITRM	2.02	3.05	2.86
2025-11-17	ITRM	2.02	2.94	2.86
2025-11-18	ITRM	2.02	2.94	2.86
2025-11-19	ITRM	2.02	2.94	2.86
2025-11-20	ITRM	2.58	2.94	2.86
2025-11-21	ITRM	2.58	2.94	0
2025-11-24	ITRM	4.85	-2.41	2.58
2025-11-25	ITRM	4.79	-2.41	2.58
2025-11-26	ITRM	4.79	-2.41	2.64
2025-12-01	ITRM	4.79	-2.21	2.64
2025-12-02	ITRM	4.79	-2.21	2.64
2025-12-03	ITRM	4.79	-2.21	2.64
2025-12-04	ITRM	4.79	-2.21	2.64
2025-12-05	ITRM	4.79	-2.21	2.64
2025-12-08	ITRM	4.79	-2.22	2.64
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.2

Avg. EPS Est. Current Quarter

-0.09

Avg. EPS Est. Next Quarter

-0.1

Insider Transactions

4.79

Institutional Transactions

-2.22

Beta

2.83

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.9

Max Drawdown 5-Year %

-99

Target Price

5.5

P/E

Forward P/E

PEG

P/S

60.68

P/B

P/Free Cash Flow

EPS

-0.75

Average EPS Est. Cur. Y

-0.59

EPS Next Y. (Est.)

-0.14

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6913.08

Relative Volume

0.64

Return on Equity vs Sector %

338.4

Return on Equity vs Industry %

353.3

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.26

EBIT Estimation

Iterum Therapeutics plc

Sector: Healthcare

Industry: Biotechnology

Employees: 9

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

stock quote shares ITRM – Iterum Therapeutics Plc Stock Price stock today

news today ITRM – Iterum Therapeutics Plc stock forecast ,stock prediction 2023 2024 2025

marketwatch ITRM – Iterum Therapeutics Plc yahoo finance google finance

stock history ITRM – Iterum Therapeutics Plc invest stock market

stock prices ITRM premarket after hours

ticker ITRM fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ITRM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y